Beam Therapeutics Inc. (BEAM)
After hours:
Chart Events
Performance Outlook
| Previous Close | 48.45 |
| Open | 47.63 |
| Bid | 46.76 x 1000 |
| Ask | 48.00 x 1000 |
| Day's Range | 46.82 - 48.38 |
| 52 Week Range | 27.77 - 80.00 |
| Volume | |
| Avg. Volume | 838,327 |
| Market Cap | 3.376B |
| Beta (5Y Monthly) | 1.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.19 |
| Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 89.45 |
- Motley Fool
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
Cathie Wood is roaring back. Her flagship ARK Innovation ETF (NYSEMKT: ARKK) plunged 67% last year. But so far in 2023, the exchange-traded fund is up nearly 40%. This impressive performance could be just the warm-up.
- TipRanks
Cathie Wood pours millions into these 2 stocks — this is what makes them attractive buys
January has now been and gone and turned out to be a nice gift for investors. Battered by 2022’s bear, the tech-heavy Nasdaq, in particular, put in an excellent showing, seeing out the month ~11% into the green, in what amounted to its best start to a year since 2001. That signals the appetite for risk is on again and that will be good news for Cathie Wood, the ARK Investment CEO, whose investing style heavily favors disruptors - equities that are naturally positioned at the risky end of the sca
- InvestorPlace
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis. As a result, companies developing CRISPR-based products and services have seen significant valuation growth since inception, with many CRISPR stocks having excellent long-term upside potential in this regard. Several companies at the forefront of CRISPR technology have seen their stocks
